Holen Sie sich die Stockscreener-App
0.207
1.86%
-0.003
Azitra Inc Aktie (AZTR) Neueste Nachrichten
Azitra Inc Financial Disclosures & SEC Filings - TradingView
Azitra Inc (AZTR) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageProfit Recovery Report - Newser
AZTR Q1 2026 Earnings: Significant EPS Miss and Stock Decline Amid Pre-Revenue StageEarnings Season Outlook - Newser
AZTR Q1 2026 Earnings: Significant EPS Miss Amidst Early-Stage DevelopmentShort-Term Outlook - Newser
AZTR Q1 2026 Earnings: Massive EPS Miss Exceeds Expectations as Stock Declines Nearly 4%Trade Idea Marketplace - Newser
Azitra (NYSE: AZTR) S-1 shows massive resale dilution and risks - Stock Titan
Azitra (AZTR) Stock: Down -1.58%, Support Test at $0.18 2026-05-19Free Stock Community - Newser
AZTR SEC FilingsAzitra Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Azitra (AZTR) Stock Analysis: Falls -2.40%, Watching $0.20 2026-05-14Profit Surge - newser.com
Azitra 1Q Loss/Shr 25c >AZTR - Moomoo
Branford biotech Azitra expands into consumer skin-care market - Hartford Business Journal
Azitra, Inc. Q1 2024 Financial Report: Operating Expenses, Net Loss, and Key Disclosures - Minichart
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates - PR Newswire
Azitra, Inc. Announces Q1 2026 Financial Results and Pipeline Milestones for Biotherapeutics and Cosmeceuticals - Minichart
Azitra (NYSE: AZTR) widens Q1 loss but lifts cash and equity via new financings - Stock Titan
Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials - TradingView
Azitra, Inc. 1Q 2026: Net loss $(3.93M), EPS $(0.25) — 10-Q Summary - TradingView
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biotech testing new rash and wrinkle treatments posts Q1 loss, $10.1M cash - Stock Titan
Azitra (NYSE: AZTR) widens Q1 2026 loss but strengthens cash and pipeline - Stock Titan
MSN Money - MSN
Number of shareholders of Azitra Inc – AMEX:AZTR - TradingView
Azitra (NYSE American: AZTR) seeks OK for big share increase and reverse split - Stock Titan
[ARS] Azitra, Inc. SEC Filing - Stock Titan
Azitra granted new U.S. patent protecting ATR-12 program - TipRanks
Azitra receives U.S. patent for Netherton syndrome treatment - Investing.com UK
Azitra receives U.S. patent for Netherton syndrome treatment By Investing.com - Investing.com Australia
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program - PR Newswire
0.67%
1.91%
Kapitalisierung:
|
Volumen (24h):